CD271 as a marker to identify mesenchymal stem cells from diverse sources before culture

María Álvarez-Viejo, Yolanda Menéndez-Menéndez, Jesús Otero-Hernández

Abstract
Mesenchymal stem cells, due to their characteristics are ideal candidates for cellular therapy. Currently, in culture these cells are defined by their adherence to plastic, specific surface antigen expression and multipotent differentiation potential. However, the in vivo identification of mesenchymal stem cells, before culture, is not so well established. Pre-culture identification markers would ensure higher purity than that obtained with selection based on adherence to plastic. Up until now, CD271 has been described as the most specific marker for the characterization and purification of human bone marrow mesenchymal stem cells. This marker has been shown to be specifically expressed by these cells. Thus, CD271 has been proposed as a versatile marker to selectively isolated and expand multipotent mesenchymal stem cells with both immunosuppressive and lymphohematopoietic engraftment-promoting properties. This review focuses on this marker, specifically on identification of mesenchymal stem cells from different tissues. Literature revision suggests that CD271 should not be defined as a universal marker to identify mesenchymal stem cells before culture from different sources. In the case of bone marrow or adipose tissue, CD271 could be considered a quite suitable marker; however this marker seems to be inadequate for the isolation of mesenchymal stem cells from other tissues such as umbilical cord blood or whatton's jelly among others.

Key words: Mesenchymal stem cells; CD271; Low-affinity nerve growth factor receptor; p75; Bone marrow stem cells

INTRODUCTION
In recent decades researchers have focused on regenerative medicine as a interesting option
for the treatment of different pathologies\textsuperscript{[1,2]}. Mesenchymal stem cells (MSC) are ideal candidates for cellular therapy due to their characteristics\textsuperscript{[3]}. MSC are viewed as clinically promising because of their differentiation capacity and pro-regenerative features\textsuperscript{[4,5]}. Moreover, MSC could be used for both autologous and heterologous transplant due to their low immunogenicity\textsuperscript{[6]}. Friedenstein et al\textsuperscript{[7]} discovered bone marrow (BM)-MSC. They demonstrated that BM contains a population of cells with a high proliferative capacity that adhere to plastic. These authors were also the first to propose the capacity of these cells to form colonies from a single cell (the fibroblast-colony forming unit F-CFU)\textsuperscript{[7,9]}. Since Friedenstein et al\textsuperscript{[7]} described MSC in the BM in the 70’s several researchers have focused their attention on this type of adult stem cell. After their initial isolation from humans, MSC have since been successfully harvested from many other species including: mouse, rat, dog and horse\textsuperscript{[10]}. They have also been isolated from almost every type of tissue, including: BM, adipose tissue, liver, skeletal muscle, amniotic fluid, umbilical cord blood (UCB) or dental pulp\textsuperscript{[11-14]}. Due to the heterogeneity of the results obtained by many groups, the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy proposes minimal criteria to define human MSC. They proposed three criteria to define MSC in culture: adherence to plastic, specific surface antigen expression and multipotent differentiation potential\textsuperscript{[15]}. All these criteria perfectly define MSC in culture, however the in vivo identification of MSC, before culture, is not as well established. In 1999, Pittenger et al\textsuperscript{[16]} described a small percentage of MSC present in BM (0.001%-0.01%) so this could explain the difficulty in establishing the exact phenotype of MSC before culture\textsuperscript{[16]}. A suitable method of selection would allow the employment of MSC in different pathologies directly after their isolation or after their in vitro expansion. Pre-culture identification markers would ensure higher purity than that obtained with selection based on adherence to plastic. Many investigators direct their efforts towards find a marker or a combination of markers to ensure their selection.

Up until now, CD271 (LNGFR) has been described as one of the most specific markers for the purification of human BM-MSCs\textsuperscript{[17,18]}. CD271, also known as low-affinity nerve growth factor receptor (LNGFR), nerve growth factor receptor (NGFR), or p75NTR (neurotrophin receptor), belongs to the tumor necrosis factor superfamily\textsuperscript{[19]}. Taking into account that this marker has been the most commonly used in the isolation of BM-MSC this review will focus on the identification of MSC from different tissues (Table 1).

**BM**

Several independent studies have confirmed the specificity of CD271 on MSC isolated from BM. At the beginning of the last decade, Quirici et al\textsuperscript{[18]} (2002) published that the anti-CD271 antibody is specific for a population of multipotent BM cells and suggested the use of this marker as an option for the selection of MSC from BM\textsuperscript{[18]}. The same year, Jones et al\textsuperscript{[20]} conducted a study in which they carried out a cellular purification from BM with antibody-conjugated magnetic beads. They found that the D7-FIB-positive fraction contained not only all the CFU-F activity but also a unique population of CD45\textsuperscript{low}/LNGFR\textsuperscript{−}/cells. These cells were adherent, proliferative, and multipotent following cell sorting and standard expansion\textsuperscript{[20]}. In 2006 the same group, suggested the need to find a way to count MSC based on the use of surface markers considering that up to this point researchers were using CFU-F assays for the enumeration of MSC. Published results demonstrate the use of flow cytometry as a rapid MSC detection method and suggested in vivo selection of the phenotype CD45\textsuperscript{low}/LNGFR\textsuperscript{−}/D7FIB\textsuperscript{+}\textsuperscript{[21]}. Following the studies started in 2002, Jones’s group continued providing more data about this marker. In a comparative study, Jones et al\textsuperscript{[22]} demonstrated that CD271 antigen (followed by CD146, CD106, D7-FIB, CD13 and CD166) remained one of the most selective markers for enriching progenitor cells from MSC of human BM. These results are supported by Kuçi et al\textsuperscript{[23,24]}, who published a study which demonstrated that the CD271 is an adequate marker for the selection of multipotent BM cells with immunosuppressive properties. Afterwards, the same group published another study in which they demonstrated that CFU-F activity was found only in the CD271\textsuperscript{+} cell fraction, whereas no CFU-F was observed in the CD271\textsuperscript{−} population\textsuperscript{[25], Flores-Torales et al\textsuperscript{[26]} (2010) proposed the use of a single marker, CD271, for the selection of MSC from BM before culture. These authors maintain that the use of this marker would reduce costs and provide a rapid and simple way of obtaining MSC. However, a high percentage of CD271\textsuperscript{+} cells in BM and synovium co-express CD34, which disqualifies CD271 as a unique marker for the isolation of MSC. Nevertheless, these studies, among others, have confirmed the usefulness of CD271 in combination with other markers such as CD45 to isolate fresh BM-MSC. Poloni et al\textsuperscript{[26]} (2009) carried out a selection of CD271 positive cells and cultivated them in a media supplemented with 10% allogeneic human sera, cells maintained the capacity to differentiate and no karyoptypic variations were observed. Our group utilized this marker (CD271\textsuperscript{+}/CD45\textsuperscript{−}) to quantify the MSC population in BM samples obtained for cell therapy using flow cytometry\textsuperscript{[27]}. Recently Mabuchi et al\textsuperscript{[28]} performed a comprehensive screening of putative surface markers to select the most useful ones for prospectively identifying a pure MSC population in human BM. They concluded that the combination marker CD271\textsuperscript{+}/CD90\textsuperscript{−}/CD106\textsuperscript{−} can
be used selectively to isolate the most potent and genetically stable MSC\textsuperscript{[28]}. Therefore, CD271 may be considered a suitable marker for determining MSC in BM.

It has been demonstrated that as the age of donors increases the number and potential for differentiation of BM MSC diminish\textsuperscript{[29]}. Taking into consideration that it is not easy to obtain such blood donors other sources for the obtention of MSC are required.

Adipose tissue is an interesting option for this end. MSCs can be isolated from fat tissue easily obtained by liposuction. It has been demonstrated that these cells are easily cultivated and have the capacity to differentiate into various cell lines\textsuperscript{[30]).}

### ADIPOSE TISSUE

In 2002 a type of stem cell from adipose tissue was isolated for the first time: adipose-derived stem cell (ADSC)\textsuperscript{[31]}. Since then, it has been demonstrated that adipose tissue provides an abundant source of MSC with similar yields to those obtained from BM. Furthermore, ADSC have a similar differentiation capability, morphology, and phenotype to MSC collected from BM\textsuperscript{[31]}. It has been shown in mice that p75NRT seems to be a useful marker for ADSC isolation\textsuperscript{[32]}. After this, Quirici \textit{et al}\textsuperscript{[33]} selected CD271\textsuperscript{+} cells immune-magnetically from ADCS in humans in a similar way as has been done from BM by others authors. CD271\textsuperscript{+} cells showed higher clonogenic and differentiation potential compared to plastic adherent ADSC. Thus these authors demonstrated the utility of this marker in the selection of ADSC cells\textsuperscript{[33]}.

### Table 1  Summary of references documenting CD271 expression in different sources

| Source                  | CD271          | Ref.                        |
|-------------------------|----------------|-----------------------------|
| Bone marrow             | Positive       | \textit{Alvarez-Viejo et al}\textsuperscript{[31]}, 2013 |
|                         |                | \textit{Flores-Torales et al}\textsuperscript{[46]}, 2010 |
|                         |                | \textit{Jones et al}\textsuperscript{[46]}, 2002; \textit{Jones et al}\textsuperscript{[46]}, 2006; \textit{Jones et al}\textsuperscript{[46]}, 2008 |
|                         |                | \textit{Kuçi et al}\textsuperscript{[46]}, 2011; \textit{Kuçi et al}\textsuperscript{[46]}, 2010 |
|                         |                | \textit{Poloni et al}\textsuperscript{[46]}, 2009 |
|                         |                | \textit{Quirici et al}\textsuperscript{[46]}, 2002 |
| Adipose tissue          | Positive       | \textit{Cuevas-Díaz Duran et al}\textsuperscript{[46]}, 2013 |
|                         |                | \textit{Quirici et al}\textsuperscript{[46]}, 2010 |
| Umbilical cord blood    | Negative       | \textit{Attar et al}\textsuperscript{[46]}, 2013 |
|                         |                | \textit{Alvarez-Viejo et al}\textsuperscript{[46]}, 2013 |
|                         |                | \textit{Watson et al}\textsuperscript{[46]}, 2013 |
| Wharton’s Jelly         | Low/negative   | \textit{Alvarez-Viejo et al}\textsuperscript{[46]}, 2013 |
|                         |                | \textit{Margossian et al}\textsuperscript{[46]}, 2012 |
| Placenta                | Positive/negative | \textit{Battula et al}\textsuperscript{[46]}, 2008 |
|                         |                | \textit{Soncini et al}\textsuperscript{[46]}, 2007 |
| Trabecular bone cavity  | Positive       | \textit{Jones et al}\textsuperscript{[46]}, 2010 |
| Dermis                  | Positive       | \textit{Vaculik et al}\textsuperscript{[46]}, 2012 |
| Peripheral blood        | Negative       | \textit{Attar et al}\textsuperscript{[46]}, 2011 |

The umbilical cord, placenta and placental membrane have been presented as cheap and attractive alternatives for the obtention of MSC\textsuperscript{[24]}.  

### UMBILICAL CORD

The UC is the structure that connects the foetus to the placenta. The UC has two arteries and a vein wrapped in a gelatinous connective tissue called Wharton’s jelly (WJ). The UC has characteristics ideal for procuring of MSC, because its use would not generate ethical conflicts, it is easily obtained and it is an abundant resource which is discarded\textsuperscript{[24]}. As described below, MSCs have been described from UCB and from WJ.

### UCB

UCB was found to contain different populations of stem cells, a unique feature not shared with peripheral blood. Some authors propose that UCB derived MSC show high morphological and molecular similarities to BM derived MSC including the lack of hematopoietic surface antigens\textsuperscript{[36]}. The presence or absence of MSC in UCB has been quite controversial. A few researchers have denied the presence of MSC in UBC such as Yu \textit{et al}\textsuperscript{[37]}, (2004) whose results suggest that early fetal blood is rich in MSC however, the term UCB is not used. On the other hand, some authors propose the difficulty in obtaining MSC from UCB to be due to their low frequency, inferior to that in BM. Up until now, the literature does not
show interesting results regarding the obtention, isolation and purification of UCB MSCs. Some publications show that the MSC can be obtained in a low percentage of UCB units (20%-63%)\cite{38,39}. These data bring into question the possibility of considering the UCB as a resource for acquiring MSC\cite{40}. However, several authors have differentiated UCB-MSC in vitro to osteogenic, chondrogenic, neural and hepatic lineages successfully\cite{41-43}. Our group has not been able to identify MSC from UCB using conventional methods of adherence to plastic. We observed a heterogeneous population of adherent cells, with a rounded and spindle-shaped appearance\cite{44}. Our results are in concordance with Perdikogianni et al\cite{45}, (2008). We also used CD271 for the presence of cells from UCB expressing this marker. Our results showed no validity for this marker in this tissue and these data are in agreement with two studies published in parallel. Attar and coworkers showed that CD271 did not contribute to isolation of MSC from UC\cite{46}. Watson et al\cite{47}, (2013) published that, CD271 is an efficient marker for MSC isolation from BM but failed to isolate MSC from UCB. Therefore, our experience and results from the literature suggest that CD271 is not a suitable marker for the identification of MSC from UCB without culture.

**WJ**

Thomas Wharton was the first to describe WJ in 1656. WJ is a gelatinous substance composed of various isoforms of collagen and proteoglycans. The principal function of WJ is to protect the arteries and veins from the compression and torsion that they can be subjected to. These provide a bidirectional flow, providing oxygen and nutrients that contribute to the adequate development of the foetus and eliminating waste and carbon dioxide\cite{48}. It has been demonstrated that human WJ-MSC present an elevated capacity for autoregeneration and have been compared with those obtained from BM\cite{39}. MSC derived from the discarded UC, more precisely WJ, offer a low-cost and pain-free collection method of MSC that may be cryogenically stored, and are considered extremely favorable for tissue engineering purposes\cite{35}. Data published by our group highlight the ineffectiveness of CD271 as a marker for the isolation of MSC from WJ before culture\cite{44}. These results are supported by data published by Margossian et al\cite{45}. They studied the expression of CD271 in situ on fresh fragments of WJ and they observed it to be weakly expressed\cite{35}. Although few studies have focused on determining the effectiveness of this marker in WJ, those that have been carried out suggest that CD271 is not a suitable marker to identify MSC from WJ before culture.

**PLACENTA**

Human placenta, plays a fundamental and essential role in fetal development, nutrition, and tolerance\cite{49}. Various reports have demonstrated that human term placenta is a plentiful source of MSC\cite{50,51}. Considering the complexity of the structure of the placenta, Parolini et al\cite{49} published a paper in order to define, as clearly as possible, the region of origin and methods of isolation of cells derived from this tissue. This work arose out the first international Workshop on Placenta Derived Stem Cells, (March 2007). One of the main characteristics is the existence of four regions in the placenta: Amniotic epithelial, amniotic mesenchymal, chorionic mesenchymal and chorionic throphoblastic. From these regions, the following cell populations are isolated: amniotic epithelial cells, amniotic mesenchymal stromal cells, chorionic mesenchymal stromal cells, chorionic trophoblastic stromal cells\cite{49}.

In 2007, Soncini et al\cite{52}, achieved the isolation of amnion mesenchymal cells (AMSC) and chorion mesenchymal cells (CMSC). These MSCs were isolated by a mechanical separation followed by enzymatic digestion. AMSC and CMSC show MSC characteristics, such as adherence to plastic, fibroblastic morphology and the capacity to form colonies. Both types of cells when analysed by flow cytometry show phenotypes similar to BM-MSC. Also, AMSC and CMSC demonstrate high plasticity when cultivated in adequate differentiating media, showing that these can differentiate into fat, bone and cartilage.

In order to isolate cells with MSC characteristics from human fetal membranes, AMSC and CMSC expressing CD271 were enriched by immunomagnetic isolation. CD271+ cells were demonstrated to possess higher clonogenic and osteogenic differentiation potentials than CD271-depleted fractions. Based on these findings, these authors suggest that amnion and chorion can be considered as a novel and convenient sources of adult MSC\cite{52}. Another study published in 2007 by Battula et al\cite{53} confirmed the possibility of obtaining MSC from chorion; however, their results showed that CD271 is not an adequate marker for the identification of MSC. They demonstrated that CD271 is expressed only at negligible levels on naive placenta MSC. Nevertheless, they identified FZD9 (frizzled-9) as a novel marker for isolation of MSC from chorionic placenta and showed that cells with CFU-F capacity reside exclusively in the FZD9+ population\cite{50}. FZD proteins comprise a family (FZD1-10) of seven transmembrane-spanning receptors\cite{53}. Based on the literature, it is still not possible to confirm CD271 as a suitable marker for the isolation of MSC from placenta.

Because of their attractiveness, researchers have attempted to isolate MSC from many tissues and their existence has been documented in several of them. Here, we discuss some studies which have referred to the use of CD271 for the identification of MSC from tissues other than those discussed above.
CD271 as a marker to identify mesenchymal stem cells

OTHER SOURCES

Chong et al[57] in 2012 demonstrated that MSC from peripheral blood maintain similar characteristics and have similar chondrogenic differentiation potential to those derived from BM. Based on the literature, we have found just one reference which documents that CD271 positive selection can not help isolation of MSC from granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood[55]. Another source is published by Jones et al[56], (2010). They showed that CD45\(^{\text{low}}\)/CD271\(^{+}\) MSC are abundant in the trabecular bone cavity and indistinguishable from aspirated CD45\(^{\text{low}}\)/CD271\(^{+}\) MSC. Moreover, MSC are found in human dermis. Vaculik et al[57] distinguished dermal MSC from differentiated fibroblasts. For this they selected CD271\(^{+}\) and SSEA-4\(^{-}\) cells from adherent dermal cells and checked their differentiation capacity. They observed that a CD271\(^{+}\) dermal population presented a greater potential for adipogenic, osteogenic and chondrogenic differentiation.

Besides CD271, several markers have been used in order to identify MSC before culture. Possibly one of the most commonly used markers for this purpose is Stro-1. After a complete review, Lv et al[58], concluded that Stro-1 expression appears not be a universal marker for MSC from different tissues. Another marker used to identify MSC is SSEA-4. It is an embryonic stem cell marker and it was documented in the isolation of genuine MSC from BM[59]. Conversely, other authors reported no detection of SSEA-4 expressing cells in unsorted BM[60,61].

Taken together, the data discussed in this review suggest that CD271 would not be considered as a universal marker to identify MSC before culture. In the case of BM or adipose tissue, CD271 could be considered a quite suitable marker for the isolation of MSC. As described in this review, several independent studies confirm the specificity of this marker in different tissues. However, CD271 is not adequate in the isolation of MSC from other tissues such as UC or UCB. Moreover, in the case of placenta contradictory results have been obtained by different groups. These contradictory results could be due to variations in the methodologies used by different laboratories. Hines et al[62] published an interesting study in which they demonstrated that membrane markers are notoriously dynamic and their expression can often be dependent on minor technical issues. Technical issues, indicating that the reproduction of results is the corner-stone of science[62].

Due to the interest in MSC for their potential applications in the clinic, it is necessary to continue research in this field, in order to find a marker or markers for optimal selection and identification of MSCs without culture. This would allow the generation of purer cultures than those obtained by adherence to plastic alone and possibly direct application avoiding cultivation costs, time and risk of contamination.

REFERENCES

1. Farini A, Sitzia C, Erratico S, Meregalli M, Torrente Y. Clinical applications of mesenchymal stem cells in chronic diseases. Stem Cells Int 2014; 2014: 306573 [PMID: 24876848 DOI: 10.1155/2014/306573]
2. Pikula M, Marek-Trzonkowska N, Wardowska A, Renkielska A, Trzonkowski P. Adipose tissue-derived stem cells in clinical applications. Expert Opin Biol Ther 2013; 13: 1357-1370 [PMID: 23919743 DOI: 10.1517/14712598.2013.823153]
3. Chan TM, Harr HJ, Lin HP, Chou PW, Chen JY, Ho TJ, Chiou TW, Chuang HM, Chiu SC, Chen YC, Yen SY, Huang MH, Liang BC, Lin SZ. Improved human mesenchymal stem cell isolation. Cell Transplant 2014; 23: 399-406 [PMID: 24816441 DOI: 10.3727/096368914X678292]
4. Das M, Sundell IB, Koka PS. Adult mesenchymal stem cells and their potency in the cell-based therapy. J Stem Cells 2013; 8: 1-16 [PMID: 24459809]
5. Dorronsoro A, Fernández-Rueda J, Fechter K, Ferrin I, Salcedo JM, Jakobsen E, Trigueros C. Human mesenchymal stromal cell-mediated immunoregulation: mechanisms of action and clinical applications. Bone Marrow Res 2013; 2013: 203643 [PMID: 24187625 DOI: 10.1155/2013/203643]
6. Bieback K. Platelet lysis as replacement for fetal bovine serum in mesenchymal stromal cell cultures. Transfus Med Hemother 2013; 40: 326-335 [PMID: 24273486 DOI: 10.1159/000354061]
7. Friedenstein AJ, Chailakhjan RK, Lalykin KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 1970; 3: 393-403 [PMID: 5523063]
8. Boxall SA, Jones E. Markers for characterization of bone marrow multipotential stromal cells. Stem Cells Int 2012; 2012: 975871 [PMID: 22666272 DOI: 10.1155/2012/975871]
9. Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2008; 2: 313-319 [PMID: 18397751 DOI: 10.1016/j.stem.2008.03.002]
10. Rastegar F, Shenaj D, Huang J, Zhang W, Zhang BQ, He BC, Chen L, Zao GW, Luo Q, Shi Q, Wagner ER, Huang E, Gao Y, Gao JL, Kim SH, Zhou JZ, Bi Y, Su Y, Zhu G, Luo J, Luo X, Qin J, Reid RR, Luo HH, Haydon RC, Deng ZL, He TC. Mesenchymal stem cells: Molecular characteristics and clinical applications. World J Stem Cells 2010; 2: 67-80 [PMID: 21607123 DOI: 10.4252/wjsc.v2.i4.67]
11. Hong SJ, Jia SX, Xie P, Xu W, Leung KP, Mustoe TA, Galiano RD. Topically delivered adipose derived stem cells show an activated-fibroblast phenotype and enhance granulation tissue formation in skin wounds. PLoS One 2013; 8: e56540 [PMID: 23383253]
12. Huang GT, Al-Habib M, Gauthier P. Challenges of stem cell-based pulp and dentin regeneration: a clinical perspective. Endod Topics 2013; 28: 51-60 [PMID: 23914150]
13. Judson RN, Zhang RH, Rossi FM. Tissue-resident mesenchymal stem/progenitor cells in skeletal muscle: collaborators or saboteurs? FEBS J 2013; 280: 4100-4108 [PMID: 23763717 DOI: 10.1111/feb.12370]
14. Strioga M, Viswanathan S, Darinskas A, Slaby O, Micheal J. Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells Dev 2012; 21: 2724-2752 [PMID: 22468918 DOI: 10.1089/scd.2011.0722]
15. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prokop D, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317 [PMID: 16923606]
16. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multipotential potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147 [PMID: 10102841]
17. Bühring HJ, Battula VL, Tremi S, Schewe B, Kanz L, Vogel W.
Novel markers for the prospective isolation of human MSC. Ann N Y Acad Sci 2007; 1106: 262-271 [PMID: 17395729]

Quirici N, Soligo D, Bosso-Lasco P, Servida F, Lumin C, Deliliers GL. Isolation of bone marrow mesenchymal stem cells by anti-neuronal growth factor receptor antibodies. Exp Hemotol 2002; 30: 783-791 [PMID: 12135677]

Thomson TM, Rettig WJ, Chesa PG, Green SH, Mena AC, Old LJ. Expression of human nerve growth factor receptor on cells derived from all three germ layers. Exp Cell Res 1988; 174: 533-539 [PMID: 2828807]

Jones EA, Kinsey SE, English A, Jones RA, Straszynski L, Meredith DM, Markham AF, Jack A, Emery P, McGonnagle D. Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. Arthritis Rheum 2002; 46: 3349-3360 [PMID: 12483742]

Jones EA, English A, Kinsey SE, Straszynski L, Emery P, Ponchel F, McGonnagle D. Optimization of a flow cytometry-based protocol for detection and phenotypic characterization of multipotent mesenchymal stromal cells from human bone marrow. Cytometry B Clin Cytom 2006; 70: 391-399 [PMID: 16977637]

Jones E, McGonnagle D. Human bone marrow mesenchymal stem cells in vivo. Rheumatology (Oxford) 2008; 47: 126-131 [PMID: 17986482]

Küçü K, Küçü S, Zircher S, Koller, Schubert R, Bönig H, Kuçi S, Zircher S, Kreyenberg H, Deak E, Pütsch K, Huenecke M. Comparative phenotype analysis between Wharton’s jelly and bone marrow derived mesenchymal stem cells for clinical use? J Cell Physiol 2010; 226: 625-634 [PMID: 15277708]

Kern S, Eichler J, Steove J, Kültér H, Bieback K. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 2004; 22: 625-634 [PMID: 15277708]

Liu G, Ye X, Zhu Y, Li Y, Sun J, Cui L, Cao Y. Osteogenic differentiation of GFP-labeled human umbilical cord blood derived mesenchymal stem cells after cryopreservation. Cytotherapy 2011; 3: 129-136 [DOI: 10.1080/14653125.2011.560161]

Poloni A, Maurizi G, Rosini V, Mondini E, Mancini S, Discepoli G, Morikawa S, Harada S, Niibe K, Suzuki S, Renault-Ménard Y, Akamatsu H, Hasegawa S, Yamada T, Nakata S, Okuma M, Miyachi E, Marunouchi T, Matsunaga K. Isolation of multipotent stem cells from mouse adipose tissue. J Dermatol Sci 2007; 48: 43-52 [PMID: 17644532]

Quirici N, Scavullo C, de Girolamo L, Lopa S, Arrigoni E, Deliliers GL, Brini AT. Anti-L-NFGR and -CD34 monoclonal antibodies identify multipotent mesenchymal stem cells in human adipose tissue. Stem Cells Dev 2010; 19: 915-925 [PMID: 19929314 DOI: 10.1089/scd.2009.0408]

Murphy SV, Atala A. Amniotic fluid and placental membranes: unexpected sources of highly multipotent cells. Semin Reprod Med 2013; 31: 62-68 [PMID: 23329638 DOI: 10.1055/s-0033-1317799]

Margarossian T, Reppel L, Makdissi N, Stoltzf J, Bensoussan D, Hauselstein C. Mesenchymal stem cells derived from Wharton’s jelly: comparative phenotype analysis between Wharton’s jelly and bone marrow derived mesenchymal stem cells. Dev Cell 2007; 13: 297-308 [PMID: 17698080]

March 26, 2015 | Volume 7 | Issue 2 | WJSC | www.wjgnet.com
Taghizadeh RR, Cetrulo KJ, Cetrulo CL. Wharton’s Jelly stem cells: future clinical applications. Placenta 2011; 32 Suppl 4: S311-S315 [PMID: 21733573 DOI: 10.1016/j.placenta.2011.06.010]

Parolini O, Alviano F, Bagnara GP, Bilic G, Bühring HJ, Evangelista M, Hennerichler S, Liu B, Magatti M, Mao N, Miki T, Marongiu F, Nakajima H, Nikaido T, Portmann-Lanz CB, Sankar V, Soncini M, Stadler G, Surbek D, Takahashi TA, Redl H, Sakuragawa N, Wolbank S, Zeisberger S, Zisch A, Strom SC. Concise review: isolation and characterization of cells from human term placenta: outcome of the first international Workshop on Placenta Derived Stem Cells. Stem Cells 2008; 26: 300-311 [PMID: 17975221]

Battula VL, Treml S, Abele H, Bühring HJ. Prospective isolation and characterization of mesenchymal stem cells from human placenta using a frizzled-9-specific monoclonal antibody. Differentiation 2008; 76: 326-336 [PMID: 17924962]

In't Anker PS, Scherjon SA, Kleijburg-van der Keur C, de Groot-Swings GM, Claas FH, Fibbe WE, Kanhai HH. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells 2004; 22: 1338-1345 [PMID: 15579651]

Soncini M, Vertua E, Gibelli L, Zorzi F, Denegri M, Albertini A, Wengler GS, Parolini O. Isolation and characterization of mesenchymal cells from human fetal membranes. J Tissue Eng Regen Med 2007; 1: 296-305 [PMID: 18038420]

Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004; 20: 781-810 [PMID: 15473860]

Chong PP, Selvaratnam L, Abbas AA, Kamarul T. Human peripheral blood derived mesenchymal stem cells demonstrate similar characteristics and chondrogenic differentiation potential to bone marrow derived mesenchymal stem cells. J Orthop Res 2012; 30: 634-642 [PMID: 21922534 DOI: 10.1002/jor.21556]

Attar A PZN, Ahrari I, Khosravi Maharlou M, Monabati A. Assessing the role of CD271 isolation from GCSF mobilized peripheral blood in isolation of MSCs. Cell J 2011; 12: 131

Jones E, English A, Churchman SM, Kouroupis D, Boxall SA, Kinsey S, Giannoudis PG, Emery P, McGonagle D. Large-scale extraction and characterization of CD271+ multipotential stromal cells from trabecular bone in health and osteoarthritis: implications for bone regeneration strategies based on uncultured or minimally cultured multipotential stromal cells. Arthritis Rheum 2010; 62: 1944-1954 [PMID: 20222109]

Vaculik C, Schuster C, Bauer W, Iram N, Pfisterer K, Kramer G, Reinisch A, Strunk D, Elbe-Bürger A. Human dermis harbors distinct mesenchymal stem cell subsets. J Invest Dermatol 2012; 132: 563-574 [PMID: 22048731 DOI: 10.1038/jid.2011.355]

Lv FJ, Tuan RS, Cheung KM, Leung VY. Concise review: the surface markers and identity of human mesenchymal stem cells. Stem Cells 2014; 32: 1408-1419 [PMID: 24578244 DOI: 10.1002/stem.1681]

Gang EJ, Bosnakovski D, Figueiredo CA, Visser JW, Pereirinho RC. SSEA-4 identifies mesenchymal stem cells from bone marrow. Blood 2007; 109: 1743-1751 [PMID: 17082733]

Tormin A, Li O, Brune JC, Walsh S, Schütz B, Ehinger M, Ditzel N, Kassem M, Scheding S. CD146 expression on primary nonhematopoietic bone marrow stem cells is correlated with in situ localization. Blood 2011; 117: 5067-5077 [PMID: 21415267 DOI: 10.1182/blood-2010-08-304287]

Wagner W, Wein F, Seekinger A, Frankhauser M, Wirker N, Krause U, Blake J, Schwager C, Eckstein V, Ansgorwe H, Ho AD. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol 2005; 33: 1402-1416 [PMID: 16263424]

Hines WC, Su Y, Kuhn I, Polyak K, Bissell MJ. Sorting out the FACs: a devil in the details. Cell Rep 2014; 6: 779-781 [PMID: 24630040 DOI: 10.1016/j.celrep.2014.02.021]
